Composition for enhancing skin elasticity or improving skin wrinkles
A composition with 2-undecanone activates autophagy in skin cells to enhance elasticity and reduce wrinkles by inhibiting MMP-1, addressing skin aging issues in cosmetic, food, and pharmaceutical applications.
Patent Information
- Application Number
- KR1020210064168
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2021-05-18
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2041-05-18
AI Technical Summary
Current solutions are inadequate for improving skin elasticity and reducing wrinkles due to external and internal factors that impair skin function, such as ultraviolet rays, fine dust, gut microorganisms, and stress hormones, leading to accelerated skin aging.
A composition comprising 2-undecanone, its salt, hydrate, or solvate is used to activate autophagy in skin cells, specifically fibroblasts, thereby inhibiting the expression of the MMP-1 enzyme and enhancing skin elasticity.
The composition effectively improves skin elasticity and reduces wrinkles by activating autophagy and inhibiting MMP-1 enzyme expression without side effects, offering formulations in cosmetic, food, and pharmaceutical forms.
Smart Images

Figure 112021057456734-PAT00002_ABST
Abstract
Description
Technology Field
[0001] This specification relates to a composition for improving skin elasticity or skin wrinkles. Background Technology
[0002] The skin is an organ located on the outermost layer of the human body that serves to protect the body from various external stimuli. Among the layers of the skin, the epidermis prevents the evaporation of moisture from within the body. The epidermis is divided into the stratum corneum, stratum granulosum, stratum spinosum, and stratum basale in order from the outside; the cells of the stratum corneum act like bricks, and the intercellular lipids between the keratinocytes act like mortar, forming the skin barrier.
[0003] It is known that normal skin function is impaired by external stimuli such as ultraviolet rays and fine dust, as well as internal causes such as metabolites produced by gut microorganisms and stress hormones, thereby accelerating phenomena such as loss of elasticity, keratinization, and wrinkle formation; however, there are currently almost no solutions to control this.
[0004] Autophagy is a process that removes unnecessary substances or waste products from within cells. Activating autophagy in fibroblasts eliminates these wastes, thereby inhibiting skin aging symptoms such as loss of elasticity, keratinization, and wrinkle formation. Therefore, there is a need to develop substances that enhance skin elasticity and improve wrinkles by activating autophagy. Prior art literature
[0005] Korean Published Patent Application No. 10-2019-0051350 The problem to be solved
[0006] In one aspect, the present invention aims to provide a composition for improving skin elasticity or improving skin wrinkles. means of solving the problem
[0007] In one aspect, the present invention provides a composition for improving skin elasticity or improving skin wrinkles comprising 2-undecanone, a salt, hydrate, or solvate thereof as an active ingredient.
[0008] In one exemplary embodiment, the 2-undecanone, salt, hydrate, or solvate composition thereof may be administered at a dosage of 1 to 170 mg / kg / day.
[0009] In an exemplary embodiment, the composition may activate intracellular autophagy.
[0010] In an exemplary embodiment, the composition may inhibit the expression of the MMP-1 enzyme.
[0011] In an exemplary embodiment, the composition may be a food composition or a cosmetic composition.
[0012] In one aspect, the present invention provides a composition for activating autophagy comprising 2-undecanone, a salt, hydrate, or solvate thereof as an active ingredient.
[0013] In an exemplary embodiment, the autophagy may be autophagy in a skin cell.
[0014] In an exemplary embodiment, the autophagy may be autophagy in skin fibroblasts.
[0015] In an exemplary embodiment, the composition may be a food composition, a cosmetic composition, or a pharmaceutical composition. Effects of the invention
[0016] In one aspect, the composition according to one embodiment of the present invention has excellent effects of improving skin elasticity and improving skin wrinkles without side effects.
[0017] In one aspect, a composition according to one embodiment of the present invention can activate autophagy within a cell.
[0018] In one aspect, a composition according to one embodiment of the present invention can inhibit the expression of MMP-1 enzyme. Brief explanation of the drawing
[0019] Figure 1 is the result of measuring the cytotoxicity of 2-undecanone according to one embodiment of the present invention. Figure 2 is the result of measuring the autophagic activation of 2-undecanone according to one embodiment of the present invention. Figure 3 is the result of measuring the inhibition of MMP-1 enzyme expression by 2-undecanone according to one embodiment of the present invention. Specific details for implementing the invention
[0020] The present invention will be described in detail below.
[0021] In one aspect, the present invention provides a composition for improving skin elasticity or improving skin wrinkles comprising 2-undecanone, a salt, hydrate, or solvate thereof as an active ingredient.
[0022] In another aspect, the present invention provides a composition for activating autophagy comprising 2-undecanone, its salt, hydrate, or solvate as an active ingredient.
[0023] In one embodiment, the 2-undecanone can be represented by the following chemical formula 1.
[0025] [Chemical Formula 1]
[0026]
[0028] In this specification, "salt" means a salt according to one aspect of the present invention that is acceptable in medicines, cosmetics and foods and has desirable activity of a parent compound. The salt is formed from (1) an inorganic acid such as hydrochloric acid, hydrobromide, sulfuric acid, nitric acid, phosphoric acid, etc.; or acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvate, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2,2,2]-oct-2-en-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, (2) may include an acid addition salt formed from an organic acid such as tert-butylacetic acid, lauryl sulfate, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, or muconic acid; or a salt formed when an acidic proton present in the parent compound is substituted. Additionally, the salt may be a pharmaceutically acceptable salt.
[0029] In this specification, “pharmaceuticalally acceptable” means that it is approved by a government or equivalent regulatory body, or listed in a pharmacopoeia, or recognized by other general pharmacopoeias, for use in animals, more specifically in humans, by avoiding significant toxic effects when used at a normal medicinal dosage.
[0030] In this specification, "hydrate" refers to a compound to which water is bound, and is a broad concept that includes inclusion compounds in which there is no chemical bonding force between the water and the compound.
[0031] In this specification, "solvent" refers to a higher-order compound formed between molecules or ions of a solute and molecules or ions of a solvent.
[0032] In this specification, "active ingredient" means an ingredient that exhibits the intended activity alone or can exhibit activity in combination with a carrier that is inactive itself.
[0033] In this specification, "autophagy" refers to a mechanism for regenerating energy and removing damaged substances by breaking down aging or damaged intracellular materials and organelles when intracellular energy sources are depleted or intracellular stress factors occur excessively. Cells can be maintained only when this autophagy occurs normally. If autophagy in the skin is inhibited, conditions such as skin pigmentation, dermatitis, acne, allergies, atopy, and psoriasis may occur.
[0034] In one embodiment, 2-undecanone, its salt, hydrate, or solvate by administration of the composition may be administered at a dosage of 1 to 170 mg / kg / day. If the dosage of 2-undecanone, its salt, hydrate, or solvate by administration of the composition is less than 1 mg / kg / day, it may be difficult to achieve skin elasticity enhancement and skin wrinkle improvement effects, and if it exceeds 170 mg / kg / day, it may irritate the skin. Specifically, the dosage of 2-undecanone, its salt, hydrate, or solvate by administration of the above composition is 1 mg / kg / day or more, 2 mg / kg / day or more, 3 mg / kg / day or more, 4 mg / kg / day or more, 5 mg / kg / day or more, 6 mg / kg / day or more, 7 mg / kg / day or more, 8 mg / kg / day or more, 9 mg / kg / day or more, 10 mg / kg / day or more, 11 mg / kg / day or more, 12 mg / kg / day or more, 13 mg / kg / day or more, 14 mg / kg / day or more, 15 mg / kg / day or more, 16 mg / kg / day or more, 17 mg / kg / day or more, 18 mg / kg / day or more, 19 mg / kg / day or more, 20 mg / kg / day or more, 21 mg / kg / day or more, 22 mg / kg / day or more, 23 It may be 170 mg / kg / day or less, 168 mg / kg / day or less, 166 mg / kg / day or less, 164 mg / kg / day or less, 162 mg / kg / day or less, 160 mg / kg / day or less, 158 mg / kg / day or less, 156 mg / kg / day or less, 154 mg / kg / day or less, 152 mg / kg / day or less, 150 mg / kg / day or less, 148 mg / kg / day or less, 146 mg / kg / day or less, 144 mg / kg / day or less, 142 mg / kg / day or less, or 140 mg / kg / day or less.
[0035] In one aspect, a composition according to one embodiment of the present invention can activate autophagy within a cell.
[0036] In one aspect, a composition according to one embodiment of the present invention can inhibit the expression of the MMP-1 (matrix metalloproteinase-1) enzyme.
[0037] In one embodiment, the autophagy may be autophagy in skin cells.
[0038] In one embodiment, the autophagy may be autophagy in skin fibroblasts.
[0039] In one embodiment, the composition may be a cosmetic composition. The cosmetic composition may have, for example, a softening lotion, an astringent lotion, a nourishing lotion, a nourishing cream, a massage cream, an eye cream, an eye essence, an essence, a cleansing cream, a cleansing lotion, a cleansing foam, a cleansing water, a pack, a powder, a body lotion, a body cream, a body essence, a body cleanser, a hair dye, a shampoo, a rinse, a hair styling agent, a hair growth agent, an ointment, a gel, a cream, a patch, a spray, a powder, and a skin-adhesive type, but is not limited thereto.
[0040] In addition, for each formulation, other ingredients other than the essential ingredients mentioned above may be appropriately selected and combined by a person skilled in the art without difficulty, depending on the type or purpose of use of other external preparations.
[0041] The above cosmetic composition may be provided in any formulation suitable for topical application. For example, it may be provided in the form of a solution, an emulsion obtained by dispersing an oil phase in an aqueous phase, an emulsion obtained by dispersing an aqueous phase in an oil phase, a suspension, a solid, a gel, a powder, a paste, a microneedle, a foam, or an aerosol composition. Compositions of such formulations may be prepared according to conventional methods in the art.
[0042] In addition to the compounds of this specification, the cosmetic composition according to this specification may further include functional additives and ingredients included in general cosmetic compositions. The functional additives may include ingredients selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, high molecular weight peptides, high molecular weight polysaccharides, sphingolipids, and seaweed extracts. The cosmetic composition according to this specification may include other ingredients that can provide a synergistic effect to the main effect, preferably within a range that does not impair the main effect. Furthermore, the cosmetic composition according to this specification may further include moisturizers, emollients, surfactants, UV absorbers, preservatives, disinfectants, antioxidants, pH adjusters, organic and inorganic pigments, fragrances, cooling agents, or limiting agents. The amount of the above ingredients can be easily selected by a person skilled in the art within a range that does not impair the purpose and effect of this specification, and the amount may be 0.001 to 10 weight%, specifically 0.01 to 3 weight%, based on the total weight of the composition.
[0043] In one embodiment, the composition may be a food composition. The formulation of the food composition is not particularly limited, but may be formulated, for example, into tablets, granules, pills, powders, liquids such as drinks, caramels, gels, bars, tea bags, etc. For each formulation of the food composition, in addition to the active ingredient, ingredients commonly used in the field can be appropriately selected and combined by a person skilled in the art according to the formulation or purpose of use without difficulty, and a synergistic effect may occur when applied simultaneously with other raw materials.
[0044] A food composition according to one embodiment may include various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavoring agents, coloring agents and promoters (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. Additionally, food compositions according to one embodiment may include fruit pulp for the production of natural fruit juices, fruit juice beverages, and vegetable beverages. These ingredients may be used independently or in combination. Although the proportion of these additives is not particularly important, they are generally included in the range of 0 to about 50 parts by weight per 100 parts by weight of the composition according to one embodiment.
[0045] In one embodiment, the composition may be a pharmaceutical composition. The pharmaceutical composition may be a composition for the prevention or treatment of atopic dermatitis, psoriasis, eczema, or flushing. The pharmaceutical composition may be administered orally, parenterally, rectally, topically, transdermally, intramuscularly, intraperitoneally, subcutaneously, etc. Formulations for oral administration may be tablets, pills, soft and hard capsules, granules, powders, granules, liquids, emulsions, or pellets, but are not limited thereto. Formulations for parenteral administration may be solutions, suspensions, emulsions, gels, injections, drops, suppositories, patches, or sprays, but are not limited thereto. The above formulation can be easily prepared according to conventional methods in the field and may additionally include surfactants, excipients, wettable powders, emulsification promoters, suspending agents, salts or buffers for osmotic pressure control, coloring agents, spices, stabilizers, preservatives, preservatives, or other commonly used auxiliary agents.
[0046] The present invention will be described in more detail below through examples and the like. These examples are solely for illustrating the present invention, and it will be obvious to those skilled in the art that the scope of the present invention is not to be interpreted as being limited by these examples.
[0048] [Experimental Example 1] Measurement of cytotoxicity
[0049] Human dermal fibroblasts (Normal human dermal fibroblast, LONZA) were placed in DMEM (Dulbecco's Modified Eagle's medium) containing 10% FBS (fetal bovine serum) and cultured at 37°C under 5% CO2 conditions. The cultured human dermal fibroblasts were treated with 2-undecanone (Sigma Aldrich) at various concentrations for 24 hours. After treating with CCK8 reagent (Donjindo, CK04) diluted to 1 / 10 in DMEM medium for 3 hours, the absorbance was measured at 450 nm, and the results are shown in Figure 1.
[0050] [Experimental Example 2] Evaluation of Autophagy Activation
[0051] To confirm the autophagy-activating effect of 2-undecanone, human-derived fibroblasts were treated with 1000 μM of 2-undecanone for 24 hours, after which the cells were lysed to produce cell lysates. Through protein quantification, cell lysates containing equal amounts of protein were separated by protein size using electrophoresis, and the relative protein expression levels of MMP-1 were confirmed by western blotting using antibodies specific to MMP-1. An equal amount of protein was used as a loading control, verified using antibodies specific to ACTB (beta-actin). At this time, siRNA of ATG5-ATG12 (Bionier), which is involved in autophagy, was co-treated as a control group, and the expression of MMP-1 was confirmed and is shown in Figure 2.
[0052] As can be seen in Figure 2, treatment with 2-undecanone activates autophagy and reduces the expression of MMP-1, but since the effect of reducing MMP-1 expression disappears upon treatment with siRNA of ATG5-ATG12, which is involved in autophagy, it was found that 2-undecanone inhibits the expression of MMP-1 by activating autophagy.
[0053] [Experimental Example 3] Evaluation of the Inhibitory Effect of MMP-1 Enzyme Expression
[0054] Human-derived fibroblasts were treated with 100 μM of 2-undecanone for 24 hours, after which they were lysed to produce cell lysates. Through protein quantification, cell lysates containing equal amounts of protein were separated by protein size using electrophoresis, and the relative protein expression levels of MMP-1 were confirmed by western blotting using an antibody specific to MMP-1. The use of equal amounts of protein was verified using an antibody specific to ACTB (beta-actin) as a loading control, and the results are shown in Figure 3.
[0056] [Formulation Example 1] Liquid ampoule
[0057] A liquid ampoule was prepared by a conventional method according to the composition listed in Table 1 below.
[0058] ingredient Content (weight%) 2-Undecanon 3.2 Arginine 0.50 Green tea polyphenols 0.05 Indigestible maltodextrin 1.00 Vitamin C 0.10 Citric acid 0.10 spices 0.05 purified water Remaining amount total 100.00
[0059] [Formulation Example 2] Soap
[0060] Soap was prepared using a conventional method according to the composition listed in Table 2 below.
[0061] ingredient Content (weight%) 2-Undecanon 3.00 titanium dioxide 0.20 polyethylene glycol 0.80 glycerin 0.50 Ethylenediaminetetraacetic acid 0.05 sodium 1.00 pigment 0.20 Soap scent 0.20 Soap base Remaining amount total 100.00
[0062] [Formulation Example 3] Lotion
[0063] A lotion was prepared using a conventional method according to the composition listed in Table 3 below.
[0064] ingredient Content (weight%) 2-Undecanon 3.00 L-ascorbic acid-2-magnesium phosphate 1.00 collagen 1.00 Sodium citrate 0.10 citric acid 0.05 Licorice extract 0.20 1,3-Butylene Glycol 3.00 purified water Remaining amount total 100.00
[0065] [Formulation Example 4] Cream
[0066] A cream was prepared using a conventional method according to the composition listed in Table 4 below.
[0067] ingredient Content (weight%) 2-Undecanon 3.00 polyethylene glycol monostearate 2.00 Self-emulsifying monostearic acid glycerin 5.00 Cetyl alcohol 4.00 Squalene 6.00 Tri-2-actylhenic acid glyceryl 6.00 sphingoglycolipid 1.00 1,3-Butylene Glycol 7.00 purified water Remaining amount total 100.00
[0068] [Formulation Example 5] Pack
[0069] A pack was manufactured using a conventional method according to the composition listed in Table 5 below.
[0070] ingredient Content (weight%) 2-Undecanon 3.00 Polyvinyl alcohol 13.00 L-ascorbic acid-2-magnesium phosphate 1.00 Lauroylhydroxyproline 1.00 collagen 2.00 1,3-Butylene Glycol 3.00 ethanol 5.00 purified water Remaining amount total 100.00
[0071] [Formulation Example 6] Liquid formulation
[0072] A cosmetic liquid formulation was prepared by a conventional method according to the composition listed in Table 6 below.
[0073] ingredient Content (weight%) 2-Undecanon 3.00 hydroxyethylenecellulose 12.00 Xanthan sword 2.00 1,3-Butylene Glycol 6.00 glycerin 4.00 sodium hyaluronate 5.00 purified water Remaining amount total 100.00
[0074] [Formulation Example 7] Soft capsule
[0075] 200 mg of 2-undecanone, 160 mg of L-carnitine, 320 mg of soybean oil, 2 mg of palm oil, 8 mg of hydrogenated vegetable oil, 4 mg of yellow beeswax, and 6 mg of lecithin were mixed and filled into one capsule according to a conventional method to produce a soft capsule.
[0077] [Formulation Example 8] Tablet
[0078] 200 mg of 2-undecanone, 500 mg of galactooligosaccharide, 80 mg of lactose, and 220 mg of maltose were mixed and granulated using a fluid bed dryer, then 6 mg of sugar ester was added and the mixture was compressed using a tablet press to produce tablets.
[0080] [Formulation Example 9] Granules
[0081] 200 mg of 2-undecanone, 250 mg of anhydrous crystalline glucose, and 550 mg of starch were mixed, formed into granules using a fluid bed granulator, and then filled into a bag to produce a granulated product.
[0083] [Formulation Example 10] Drink
[0084] 170 mg of 2-undecanone, 10 g of glucose, 0.6 g of citric acid, and 25 g of liquid oligosaccharide were mixed, and 500 ml of purified water was added to fill each bottle with 200 ml. After filling the bottles, the mixture was sterilized at 130°C for 4 to 5 seconds to produce a drinkable beverage.
Claims
Claim 1 A composition for preventing a decrease in skin elasticity or the formation of skin wrinkles by activating autophagy in skin fibroblasts, comprising 2-undecanone, its salt, hydrate, or solvate as an active ingredient. Claim 2 A composition according to claim 1, wherein the 2-undecanone, its salt, hydrate, or solvate is administered at a dosage of 1 to 170 mg / kg / day. Claim 3 delete Claim 4 In claim 1, the composition is a composition that inhibits the expression of MMP-1 enzyme. Claim 5 In any one of paragraphs 1, 2 and 4, the composition is a food composition. Claim 6 A composition in any one of claims 1, 2 and 4, wherein the composition is a cosmetic composition. Claim 7 A cosmetic composition for activating autophagy in skin fibroblasts, comprising 2-undecanone, its salt, hydrate, or solvate as an active ingredient. Claim 8 In claim 7, the above 2-undecanone, its salt, hydrate, or solvate is a cosmetic composition administered at a dosage of 1 to 170 mg / kg / day. Claim 9 A food composition for the prevention or improvement of skin diseases caused by reduced autophagy in skin fibroblasts, comprising 2-undecanone, its salt, hydrate, or solvate as an active ingredient. Claim 10 In claim 9, the above 2-undecanone, its salt, hydrate, or solvate is a food composition administered at a dosage of 1 to 170 mg / kg / day. Claim 11 A pharmaceutical composition for the prevention or treatment of skin diseases caused by reduced autophagy in skin fibroblasts, comprising 2-undecanone, its salt, hydrate, or solvate as an active ingredient. Claim 12 In claim 11, the above 2-undecanone, its salt, hydrate, or solvate is a pharmaceutical composition administered at a dosage of 1 to 170 mg / kg / day. Claim 13 delete
Citation Information
Patent Citations
Improved antiperspirant composition
JP2016532654A
